Share this video  

ESMO Breast 2023 | Exploring novel therapeutic approaches in HR+/ HER2- mBC

Komal Jhaveri, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the most promising novel therapies that have emerged in recent years, while drawing comparisons to the existing therapeutic interventions currently recommended for the treatment of hormone receptor+/ HER2- (HR+/ HER2-) metastatic breast cancer (mBC). Dr Jhaveri discusses the particular sensitivity of ESFR1 mutated patients to oral SERDs such as elacestrant, as well as touching on the favourable response patients with PI3K mutations exhibit to alpelisib and fulvestrant in the post CDK4/6 setting. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.